LEADER 02210nam  2200457z- 450 
001 9910346734903321
005 20210211
035   $a(CKB)4920000000094361
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/45510
035   $a(oapen)doab45510
035   $a(EXLCZ)994920000000094361
100   $a20202102d2019      |y         0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aDrug Repositioning: Current Advances and Future Perspectives
210   $cFrontiers Media SA$d2019
215   $a1 online resource (153 p.)
225 1 $aFrontiers Research Topics
311 08$a2-88945-696-X 
330   $aDrug repositioning is the process of identifying new indications for existing drugs. At present, the conventional de novo drug discovery process requires an average of about 14 years and US$2.5 billion to approve and launch a drug. Drug repositioning can reduce the time and cost of this process because it takes advantage of drugs already in clinical use for other indications or drugs that have cleared phase I safety trials but have failed to show efficacy in the intended diseases. Historically, drug repositioning has been realized through serendipitous clinical observations or improved understanding of disease mechanisms. However, recent technological advances have enabled a more systematic approach to drug repositioning. This eBook collects 16 articles from 112 authors, providing readers with current advances and future perspectives of drug repositioning.
517   $aDrug Repositioning
606   $aPharmacology$2bicssc
610   $acomputational analysis
610   $adata sharing
610   $adatabase
610   $aDrug Repositioning
610   $aIntegrative strategies
610   $amolecular docking
610   $amulti-omics
610   $aPatenting
610   $apolypharmacology
615  7$aPharmacology
700   $aYuhei Nishimura$4auth$01305940
702   $aHideaki Hara$4auth
906   $aBOOK
912   $a9910346734903321
996   $aDrug Repositioning: Current Advances and Future Perspectives$93028044
997   $aUNINA